|
Sex (men/women), n (%)
|
16 (66.7)/8 (33.3)
|
3 (42.9)/4 (57.1)
|
0.26
|
|
Age (years)
|
41.8 ± 17.1
|
48.0 ± 17.8
|
0.43
|
|
Disease duration (years)*
|
6.5 ± 4.1
|
9.6 ± 9.2
|
0.23
|
|
Modified Truelove and Witts severity index*
|
9.7 ± 3.2
|
10.6 ± 3.4
|
0.57
|
|
Mayo score (endoscopy)*
|
2.8 ± 0.4
|
2.9 ± 0.3
|
0.58
|
|
Extent of disease
| | | |
|
Left-side type, n (%)
|
12 (50.0)
|
1 (14.3)
|
0.09
|
|
Extensive colitis, n (%)
|
12 (50.0)
|
6 (85.7)
|
|
Concomitant medications
| | | |
|
Corticoteroids, n (%)
|
9 (37.5)
|
1 (14.3)
|
0.25
|
|
Azathioprine/Mercaptopurine, n (%)
|
11 (45.8)
|
4 (57.1)
|
0.60
|
|
Tacrolimus, n (%)
|
8 (33.3)
|
4 (57.1)
|
0.26
|
|
Cytemegalovirus, n (%)
|
6 (25.0)
|
4 (57.1)
|
0.17
|
|
Serum hemoglobin level >9.8 g/dl at IFX initiation, n (%)
|
16 (66.7)
|
2 (28.6)
|
0.07
|
|
Serum albumin level >35 g/L at IFX initiation, n (%)
|
12 (50.0)
|
1 (14.3)
|
0.21
|
|
Serum CRP level <5 mg/L at 2 weeks after IFX initiation, n (%)
|
18 (75.0)
|
1 (14.3)
|
0.006
|
